SUMMARY Two groups of four-year survivors with acute lymphoblastic leukaemia (ALL) are compared: an 'old' series consisting of 83 patients diagnosed before 1968, and a 'new' series of 366 patients included in Medical Research Council trials (UKALL I-III) and diagnosed in 1970-4. Both series differed significantly from a group of ALL patients who survived less than four years in having lower total leucocyte and blast-cell counts at diagnosis, but the new series did not show the significant differences in organ involvement and platelet count seen in the old series.
sponding group of the old series. About 90 % of patients achieving four years' continuous complete remission on these UKALL regimes seem likely to survive for 10 years.
In 1973 we analysed the subsequent fate of 100 patients collected from all over the British Isles' who had survived more than four years after diagnosis of acute leukaemia. Most of these patients had received much less chemotherapy than would now be considered appropriate, and they were obviously a highly selected group, representing only a very small proportion of those diagnosed as having leukaemia during the period in question . Among the 83 patients with acute lymphoblastic leukaemia (ALL), disease-free survival for four years appeared to carry about a 70% chance of very long survival, and perhaps cure, whereas the corresponding chance for those who had survived four years despite one or more previous relapses was only about 17 %.
Since the time of diagnosis of these patients, the outlook for patients with ALL, and particularly for children, has been greatly improved by the introduction of continued combination chemotherapy and 'prophylactic' treatment of the central nervous system. In Britain, important contributions to these advances have been The sex distribution of both series of patients is shown in Table 2 . In the new series, significantly more girls than boys survived for four years (62% versus 49 %; P < 0 01), and the sex difference in the proportion of four-year complete remissions was still greater (53% versus 31%; P < 010001). Although such calculations cannot be performed in the case of the old series, since the starting population is undefined, there is no reason to suppose that the sex incidence of ALL has altered during the last 30 years. The similarity of the sex ratios in both series in respect of both four-year survivals and four-year complete remissions therefore suggests that the female sex carried a proportionately similar advantage for patients treated by oldfashioned and by modern methods. Of the boys, 45 % in the old series but only 27 % in the new series were aged over 6 years at diagnosis (P < 0-05); the corresponding proportions of older girls were 21 % and 32 % (not significant).
FEATURES AT DIAGNOSIS
The proportion of patients in each series with clinical enlargement of spleen, liver, or lymph nodes The most important determinant of prognosis from four years onwards is the occurrence of a relapse within the first four years after diagnosis; in both series, the subsequent survival of patients remaining in continuous complete remission for four years is highly significantly more favourable (P < 0-0001) than that of patients who had suffered one or more prior relapses (Fig. 2) The relapse rates patients in the new se remission four years Figure 3 . Only five of relapsed are girls. significant (P < 0-00 isolated testicular rela greater risk of relap beyond four but per (Fig. 3) . The differen( however, which are r boys (P < 0*001), is a proportion of boys t four years rather tha rhaps not beyond seven years Why should the outlook for those achieving ce in subsequent survival rates, four-year complete remissions be better now than much greater for girls than for formerly? A possible explanation is that this group attributable chiefly to the higher now consists mainly of patients whose leukaemic than girls who relapsed before cell population has been eradicated by the treatment, in afterwards (Table 2) .
whereas the old series contained a higher proportion of patients whose leukaemic cell line had not been eradicated but was merely characterised by a Females 5/149 naturally slow rate of proliferation. Suboptimal chemotherapy would be expected to produce long remission without eradication of the disease in such cases, and the relapses soon after four years would represent the tail end of the distribution curve of natural proliferation rate of individual leukaemic cell lines. Some support for this concept is provided by the higher proportions in the old series of patients without organ enlargement at diagnosis and with low total blast-cell counts.
The benefit conveyed by female sex, which is ; 10 quite independent of blast-cell count at diagnosis, diagnosis is associated in both series with reduced relapse rate inuous remissions (new series): during the first four years and, in the new series, bsequent remission duration by sex. perhaps the first seven years after diagnosis. This 252 no release ( 8/270 could be explained by citing the testes as a reservoir site for leukaemic cells in boys or, since the incidence of ALL has always been greater in boys than in girls, by some more fundamental hormonal effect.
